Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 4 | 6 |
| 1.1 List of Tables | 7 | 2 |
| 1.2 List of Figures | 9 | 1 |
| 2 Personalized Medicine Market: Market Overview | 10 | 5 |
| 2.1 Introduction | 10 | 2 |
| 2.1.1 Potential Applications of Personalized Medicine | 12 | 1 |
| Optimization of Therapy | 12 | 1 |
| 2.1.1.2 Safer and Effective Drugs - Reduce Adverse Drug Reactions | 12 | 1 |
| 2.1.1.3 Reduce time, cost and failure rate of clinical trials | 13 | 1 |
| 2.1.1.4 Preventive rather than curative approach | 13 | 1 |
| 2.1.1.5 Rescue drugs failing in the market | 13 | 1 |
| 2.2 GBI Research Report Guidance | 14 | 1 |
| 3 Personalized Medicine Market: Drivers and Barriers | 15 | 4 |
| 3.1 Drivers | 16 | 1 |
| Increase in healthcare costs | 16 | 1 |
| 3.1.2 Advantages over conventional drug discovery methods | 16 | 1 |
| 3.1.3 Patient compliance | 16 | 1 |
| 3.1.4 Early detection of disease | 17 | 1 |
| 3.1.5 Better regulatory norms and validation procedures encourage growth of the personalized medicine market | 17 | 1 |
| 3.2 Barriers | 17 | 1 |
| 3.2.1 Payer Reimbursement Issues | 17 | 1 |
| 3.2.2 Ethical Issues | 17 | 1 |
| 3.2.3 Medical Information Technology | 18 | 1 |
| 3.2.4 Awareness Gap Lack of Physician Education and Awareness about Novel Technologies | 18 | 1 |
| 3.2.5 Cumbersome and Lengthy Development Procedure Discourages Biomarker Research by the Pharmaceutical Sector | 18 | 1 |
| 4 Personalized Medicine Market Personalized Therapeutics and Diagnostics | 19 | 61 |
| Personalized Therapeutics Drug Profiles | 19 | 1 |
| 4.1.1 Herceptin (trastuzumab) | 19 | 1 |
| 4.1.1.1 Overview | 19 | 1 |
| 4.1.1.2 Efficacy | 20 | 1 |
| 4.1.1.3 Safety | 20 | 1 |
| 4.1.1.4 Pricing | 20 | 1 |
| 4.1.1.5 Clinical Study Details | 20 | 1 |
| 4.1.1.6 Clinical Study Details (Herceptin for HER2-positive stomach (gastric) cancer) | 21 | 1 |
| 4.1.1.7 Lifecycle Management Activities | 22 | 1 |
| 4.1.1.8 Drug Sales | 23 | 1 |
| 4.1.1.9 SWOT Analysis | 24 | 1 |
| 4.1.2 Erbitux (cetuximab) | 24 | 1 |
| Overview | 24 | 1 |
| 4.1.2.2 Efficacy | 25 | 1 |
| 4.1.2.3 Safety | 25 | 1 |
| 4.1.2.4 Pricing | 25 | 1 |
| 4.1.2.5 Clinical Study Details | 25 | 1 |
| 4.1.2.6 Lifecycle Management Activities | 25 | 1 |
| 4.1.2.7 Drug Sales | 26 | 2 |
| 4.1.2.8 SWOT Analysis | 28 | 1 |
| 4.1.3 Gleevec (imatinib) | 28 | 1 |
| Overview | 28 | 1 |
| 4.1.3.2 Efficacy | 29 | 1 |
| 4.1.3.3 Safety | 29 | 1 |
| 4.1.3.4 Pricing | 29 | 1 |
| 4.1.3.5 Clinical Study Details | 29 | 1 |
| 4.1.3.6 Lifecycle Management Activities | 29 | 2 |
| 4.1.3.7 Drug Sales | 31 | 1 |
| 4.1.3.8 SWOT Analysis | 32 | 1 |
| 4.1.4 Zyprexa (olazapine) | 32 | 1 |
| Overview | 32 | 1 |
| 4.1.4.2 Efficacy | 32 | 1 |
| 4.1.4.3 Safety | 32 | 1 |
| 4.1.4.4 Pricing | 33 | 1 |
| 4.1.4.5 Clinical study details | 33 | 1 |
| 4.1.4.6 Lifecycle Management Activities | 33 | 1 |
| 4.1.4.7 Drug Sales | 34 | 1 |
| 4.1.4.8 SWOT Analysis | 35 | 1 |
| 4.1.5 Lipitor (atorvastatin) | 35 | 1 |
| Overview | 35 | 1 |
| 4.1.5.2 Efficacy | 36 | 1 |
| 4.1.5.3 Safety | 36 | 1 |
| 4.1.5.4 Pricing | 36 | 1 |
| 4.1.5.5 Clinical Study Details | 36 | 1 |
| 4.1.5.6 Lifecycle Management Activities | 36 | 2 |
| 4.1.5.7 Drug Sales | 38 | 1 |
| 4.1.5.8 SWOT Analysis | 39 | 1 |
| 4.1.6 Celebrex (celecoxib) | 39 | 1 |
| Overview | 39 | 1 |
| 4.1.6.2 Efficacy | 39 | 1 |
| 4.1.6.3 Safety Profile | 39 | 1 |
| 4.1.6.4 Pricing | 39 | 1 |
| 4.1.6.5 Clinical Study Details | 39 | 1 |
| 4.1.6.6 Lifecycle Management Activities | 40 | 1 |
| 4.1.6.7 Drug Sales | 41 | 1 |
| 4.1.6.8 SWOT Analysis | 42 | 1 |
| 4.1.7 Tarceva (erlotinib) | 42 | 1 |
| Overview | 42 | 1 |
| 4.1.7.2 Efficacy | 42 | 1 |
| 4.1.7.3 Safety | 43 | 1 |
| 4.1.7.4 Pricing | 43 | 1 |
| 4.1.7.5 Clinical study details | 43 | 1 |
| 4.1.7.6 Drug Sales | 44 | 1 |
| 4.1.7.7 SWOT Analysis | 45 | 1 |
| 4.1.8 Rituxan (rituximab) | 46 | 1 |
| Overview | 46 | 1 |
| 4.1.8.2 Efficacy | 46 | 1 |
| 4.1.8.3 Safety Profile | 46 | 1 |
| 4.1.8.4 Pricing | 46 | 1 |
| 4.1.8.5 Clinical Study Details | 46 | 1 |
| 4.1.8.6 Drug Sales | 47 | 1 |
| 4.1.8.7 SWOT Analysis | 48 | 1 |
| 4.1.9 Plavix (clopidogrel bisulfate) | 49 | 1 |
| Overview | 49 | 1 |
| 4.1.9.2 Efficacy | 49 | 1 |
| 4.1.9.3 Safety | 49 | 1 |
| 4.1.9.4 Lifecycle Management Activities | 49 | 1 |
| 4.1.9.5 Drug Sales | 50 | 1 |
| 4.1.9.6 SWOT Analysis | 51 | 1 |
| 4.1.10 Risperdal (risperidone) | 51 | 1 |
| Overview | 51 | 1 |
| 4.1.10.2 Efficacy | 52 | 1 |
| 4.1.10.3 Safety | 52 | 1 |
| 4.1.10.4 Clinical Study Details | 52 | 1 |
| 4.1.10.5 Lifecycle Management Activities | 52 | 1 |
| 4.1.10.6 Drug Sales | 53 | 1 |
| 4.1.10.7 SWOT Analysis | 54 | 1 |
| 4.1.11 Vectibix (Panitumumab) | 54 | 1 |
| 4.1.11.1 Overview | 54 | 1 |
| 4.1.11.2 Efficacy | 54 | 1 |
| 4.1.11.3 Safety | 55 | 1 |
| 4.1.11.4 Pricing | 55 | 1 |
| 4.1.11.5 Clinical Study Details | 55 | 1 |
| 4.1.11.6 Lifecycle Management Activities | 55 | 1 |
| 4.1.12 Coumadin (Warfarin) | 56 | 1 |
| Overview | 56 | 1 |
| 4.1.12.2 Efficacy | 56 | 1 |
| 4.1.12.3 Safety | 56 | 1 |
| 4.1.12.4 Pricing | 56 | 1 |
| 4.1.12.5 Clinical Study Details | 56 | 1 |
| 4.1.13 Iressa (Gefitinib) | 57 | 1 |
| Overview | 57 | 1 |
| 4.1.13.2 Efficacy | 57 | 1 |
| 4.1.13.3 Safety | 58 | 1 |
| 4.1.13.4 Pricing | 58 | 1 |
| 4.1.13.5 Clinical study details | 58 | 1 |
| 4.1.13.6 Lifecycle Management Activities | 58 | 1 |
| 4.1.14 Sprycel | 59 | 1 |
| Overview | 59 | 1 |
| 4.1.14.2 Efficacy | 59 | 1 |
| 4.1.14.3 Safety | 60 | 1 |
| 4.1.14.4 Lifecycle Management Activities | 60 | 1 |
| 4.1.15 Camptosar | 61 | 1 |
| Overview | 61 | 1 |
| 4.1.15.2 Efficacy | 61 | 1 |
| 4.1.15.3 Safety | 61 | 1 |
| 4.1.15.4 Clinical Study Details | 61 | 1 |
| 4.1.15.5 Pricing | 61 | 1 |
| 4.1.15.6 Lifecycle Management Activities | 61 | 1 |
| Companion Diagnostics | 62 | 2 |
| 4.2.1 Selected Companion Diagnostics Employed in Personalized Healthcare | 64 | 1 |
| 4.2.1.1 AmpliChip CYP450 | 64 | 1 |
| Oncotype Dx | 64 | 1 |
| 4.2.1.3 MammaPrint | 64 | 1 |
| 4.2.1.4 Theros breast cancer index | 64 | 1 |
| 4.2.1.5 Mammostrat | 64 | 1 |
| HercepTest | 65 | 1 |
| 4.2.1.7 DakoCytomation EGFR pharmDx | 65 | 1 |
| 4.2.1.8 eQ-PCR LC Warfarin Genotyping Kit. | 65 | 1 |
| 4.2.1.9 PGx Predict:Rituximab | 65 | 1 |
| 4.2.1.10 PhyzioType PIMS (Psychotropic-Induced Metabolic Symptoms) | 66 | 1 |
| 4.2.1.11 THERO CancerTYPE ID | 66 | 1 |
| 4.2.1.12 CupPrint | 66 | 1 |
| 4.2.1.13 HER2 FISH pharmDx Kit | 66 | 1 |
| 4.2.1.14 AlloMap gene profile | 66 | 1 |
| 4.2.1.15 Target GI Test | 67 | 1 |
| 4.3 Biomarkers | 67 | 1 |
| 4.3.1 Biomarkers in Cancer Research | 68 | 1 |
| 4.3.2 Market Size and Forecasts | 69 | 1 |
| Segmentation by Indication | 70 | 1 |
| 4.3.3.1 Breast cancer | 71 | 1 |
| 4.3.3.2 Prostate cancer | 72 | 1 |
| 4.3.3.3 Lung cancer | 73 | 1 |
| 4.3.3.4 Colorectal cancer | 74 | 1 |
| Cervical cancer | 75 | 1 |
| 4.3.3.6 Head and neck cancer | 76 | 1 |
| 4.3.3.7 Pancreatic cancer | 77 | 1 |
| 4.3.3.8 Ovarian cancer | 78 | 1 |
| 4.3.3.9 Stomach cancer | 79 | 1 |
| 5 Personalized Medicine Market: Selected Pipeline Product Profiles | 80 | 8 |
| PF-4948568 (Pfizer) | 80 | 1 |
| 5.1.1 Overview | 80 | 1 |
| 5.1.2 Mechanism of Action | 80 | 1 |
| 5.1.3 Clinical Study Details | 80 | 1 |
| 5.2 PF-02341066 + Erlotinib (Pfizer) | 81 | 1 |
| 5.2.1 Overview | 81 | 1 |
| 5.2.2 Mechanism of Action | 81 | 1 |
| 5.2.3 Clinical study details | 81 | 1 |
| 5.3 PF-299804 (Pfizer) | 82 | 1 |
| Overview | 82 | 1 |
| 5.3.2 Mechanism of action | 82 | 1 |
| 5.3.3 Clinical study details | 82 | 1 |
| 5.4 CEP-701 (Cephalon Inc.) | 83 | 1 |
| 5.4.1 Overview | 83 | 1 |
| 5.4.2 Mechanism of action | 83 | 1 |
| 5.4.3 Clinical study details | 84 | 1 |
| TBR-652 (Tobira Therapeutics, Inc) | 84 | 1 |
| 5.5.1 Overview | 84 | 1 |
| 5.5.2 Mechanism of action | 84 | 1 |
| 5.5.3 Clinical study details | 85 | 1 |
| Brivanib (Bristol-Myers Squibb) | 85 | 1 |
| 5.6.1 Overview | 85 | 1 |
| 5.6.2 Mechanism of action | 85 | 1 |
| 5.6.3 Clinical study details | 86 | 1 |
| 5.7 Ipilimumab (Bristol-Myers Squibb) | 86 | 1 |
| 5.7.1 Overview | 86 | 1 |
| 5.7.2 Mechanism of Action | 86 | 1 |
| 5.7.3 Clinical Study Details | 86 | 1 |
| BiovaxID (Accentia Biopharmaceuticals, Inc.) | 87 | 1 |
| 5.8.1 Overview | 87 | 1 |
| 5.8.2 Mechanism of Action | 87 | 1 |
| 5.8.3 Clinical Study Details | 87 | 1 |
| 6 Personalized Medicine Market: Research Trends in Personalized Medicine | 88 | 1 |
| 7 Personalized Medicine Market: Competitive Landscape | 89 | 28 |
| Competitive Profiling | 89 | 1 |
| 7.2 Clarient, Inc. | 89 | 1 |
| 7.2.1 Business Description | 89 | 1 |
| 7.2.2 Pipeline | 90 | 1 |
| 7.2.3 Major Products | 90 | 1 |
| 7.2.3.1 Clarient breast cancer test | 90 | 1 |
| 7.2.3.2 Head and neck cancer assay | 90 | 1 |
| 7.2.3.3 Insight Dx colon cancer marker | 90 | 1 |
| 7.2.3.4 Insight Dx Leukemia marker | 90 | 1 |
| 7.2.3.5 Mammostrat Basal | 90 | 1 |
| 7.2.4 Partnership and Merger and Acquisition (M&A) Deals | 91 | 1 |
| 7.3 Qiagen N.V. | 92 | 1 |
| 7.3.1 Business Description | 92 | 1 |
| 7.3.2 Pipeline | 92 | 1 |
| 7.3.3 Major Products | 92 | 1 |
| 7.3.3.1 ABL Assay | 92 | 1 |
| 7.3.3.2 Artus CMV (cytomegalovirus) assay | 92 | 1 |
| 7.3.3.3 Artus EBV (Epstein-Barr virus) | 93 | 1 |
| 7.3.3.4 Artus HSV 1/2 RG 6000 | 93 | 1 |
| 7.3.3.5 B-Raf Test-Colon Cancer | 93 | 1 |
| 7.3.4 Partnership and M&A Deals | 94 | 2 |
| 7.4 Laboratory Corporation of America Holdings | 96 | 1 |
| 7.4.1 Business Description | 96 | 1 |
| 7.4.2 Pipeline | 96 | 1 |
| 7.4.3 Major Products | 96 | 1 |
| 7.4.3.1 OvaSure | 96 | 1 |
| 7.4.4 Partnership and M&A Deals | 97 | 2 |
| 7.5 bioMerieux S.A. | 99 | 1 |
| 7.5.1 Business Description | 99 | 1 |
| 7.5.2 Pipeline | 99 | 1 |
| 7.5.3 Major Products | 99 | 1 |
| 7.5.3.1 Annexin A3 Test | 99 | 1 |
| 7.5.3.2 Breast cancer theranostic assay | 99 | 1 |
| 7.5.3.3 Point of care testing device | 99 | 1 |
| 7.5.4 Partnership and M&A Deals | 100 | 2 |
| 7.5.5 Partnership and M&A Deals | 102 | 1 |
| 7.6 Pfizer | 102 | 1 |
| 7.6.1 Business Overview | 102 | 1 |
| 7.6.2 Partnership and M&A Deals | 103 | 1 |
| 7.6.2.1 Wyeth Expands Co-Development Agreement With Caprion Pharmaceuticals June 2005 | 103 | 1 |